Shortwave presents an IP-driven, biotechnologically focused approach to the development of regulatorily-feasible formulations and delivery methods of psychedelics based medicine, addressed at unmet critical needs of patients suffering from mental health disorders, neurodegenerative diseases and chronic pain. Shortwave’s initial program focuses on treatment-resistant anorexia nervosa, an area with high mortality and morbidity, recognized by the FDA as an acute unmet need eligible for treatment by psychedelics SWP’s leadership team and partners combine years of experience in psychedelics-assisted psychotherapy, drug development and clinical research. The Company's current program consists of a novel combination of psychedelic compounds including psilocybin at a high dose intended for concentrated use as part of for psychedelics -assisted psychotherapy. Future programs consist of novel formulations administering low-dose treatment via controlled dose delivery methods intended for repeated use.